SEC Form 4 · accession 0001179110-17-002572
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexandra Glucksmann
Officer — Chief Operating Officer
Period of report
Feb 15, 2017
Accepted (ET)
Feb 16, 2017 · 6:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2017 | M | 6,000 | $0.65 | A | 123,788 | D | |
| Common Stock | Feb 15, 2017 | S | 5,000 | $20.00 | D | 118,788 | D | |
| Common Stock | Feb 15, 2017 | S | 1,000 | $23.4844 | D | 117,788 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.65 | Feb 15, 2017 | M | 6,000 | D | — | Apr 15, 2025 | Common Stock | 6,000 | 31,461 | D |
Explanation of responses
- F1The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016.
- F2This option was granted on April 16, 2015 and is scheduled to vest over four years with 25% of the shares having vested on March 9, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through March 9, 2019.